Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins

Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis

“…Several studies have investigated the prognostic value of cardiac troponin in cardiac amyloidosis 17, 18, 19, 20. However, there are only a few studies that evaluated the diagnostic utility of cardiac troponin in patients suspected of cardiac amyloidosis and compared the levels between cardiac amyloidosis and cardiac hypertrophy of non‐cardiac amyloidosis aetiologies.…”

“…It has been reported that cardiac troponin levels are higher in patients with cardiac amyloidosis compared with other forms of cardiomyopathy and high levels of cardiac troponin predict poor prognosis using conventional or high sensitive assays 6, 16, 17, 18, 19, 20. However, the utility of cardiac troponin level for the diagnosis of cardiac amyloidosis has not been fully evaluated.…”

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis

“…Abnormalities in strain echocardiography [59], elevation of the N terminal Pro brain natriuretic peptide (NT-Pro BNP) [60], and elevation of cardiac troponins [61] are seen in a wide variety of cardiac disorders, and the sensitivity and specificity of these tests compared with echocardiography have not been evaluated sufficiently for these variables to be incorporated as criteria of cardiac involvement. Myocardial amyloid is excluded by normal values of NT-Pro BNP [62].…”

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

“…Patients with cardiac involvement can present with fatigue, progressive dyspnea on exertion, diastolic dysfunction, left ventricular hypertrophy in the absence of hypertension or valvular disease, pericardial effusion, and low voltage on electrocardiogram. 25 The cardiac biomarkers N-terminal prohormone of brain natriuretic peptide (NT-proBNP) 26 and troponin T (or I) 27 are prognostic with respect to survival in AL patients, and a system incorporating these biomarkers is currently in use, with patients Figure 1. Patients in this international case series from seven centers were analyzed for survival at 3 months after beginning therapy based on metrics for hematologic response assessed at 6 months.…”